NCT00136955 - Irinotecan Study For Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Uterine Cervical Neoplasms

Interventions

DRUG

Irinotecan

An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix

Trial Locations (5)

112

Pfizer Investigational Site, Taipei

813

Pfizer Investigational Site, Kaoshiung

Unknown

Pfizer Investigational Site, Kwei-Shan County, TaoYuan,

Pfizer Investigational Site, Taichung

Pfizer Investigational Site, Taipei